Gymnema Sylvestre: A Comprehensive Reference
1. Identity, Botanical Classification, and Common Forms
Taxonomic Identity
Gymnema sylvestre is a plant in the family Apocynaceae, located in many regions of Asia, Africa, and Australia. Its accepted scientific binomial is Gymnema sylvestre (Retz.) R.Br. ex Schult. Synonyms in older literature include Periploca sylvestris; common names include Gurmar, Gurmarbooti, Kogilam, Madhunashini, Meshashringi, Meshavalli, Miracle plant, Periploca of the woods, Podapatri, Ram's horn, Sarkaraikolli, Shardunika, Sirukurinja, and Small Indian ipecac.
In Hindi, it is called Gurmar, meaning "sugar destroyer," a direct reference to its best-known effect: temporarily suppressing the ability to taste sweetness and helping reduce sugar cravings. The botanical name Gymnema comes from the Greek gymnos ("naked") and nema ("thread"), a reference to the plant's thread-like climbing growth habit.
Plant Description and Natural Source
Gymnema sylvestre is a woody climbing shrub native to the tropical forests of India, Africa, and Australia. It can be found growing in tropical and subtropical regions, especially parts of central and southern India, tropical Africa, and some parts of China, Malaysia, and Sri Lanka. The leaves are most commonly used, but the stem also appears to have some drug action.
Common Commercial Forms and Preparations
Dietary supplements and teas that contain gymnema are usually made from the leaves that grow on the vine. As it is used against major diseases such as cardiovascular disease, asthma, cancer, diabetes, and obesity, it is prepared in a variety of forms, including tea bags, nutrition tablets, and dietary supplements. Standardized extracts are the predominant commercial form; clinical studies investigating antidiabetic effects have typically used 200 or 400 mg extract daily standardized to contain 25% gymnemic acids. Some products are standardized to higher concentrations. Some trials used 400 mg per day of a concentrated extract standardized to 25% gymnemic acids, while others used whole leaf powder at doses of 2 to 6 grams daily.
2. Traditional and Historical Use
Ayurvedic Medicine (India)
Practitioners of Ayurveda, India's traditional medicine, first used gymnema to treat diabetes almost two thousand years ago. The plant, literally known under names meaning "tamer of sugar" in Sanskrit, has its earliest documented mention in the ancient Charaka Samhita (circa 1000–200 BCE), where it is prescribed under the name Meṣaśṛṅgī for conditions described as "Madhumeha," a term now correlated with high blood sugar and excessive urination.
Ayurveda, the ancient Indian system of natural healing, traditionally used it to help manage diabetes, high cholesterol, and digestive complaints, attributing to it anti-inflammatory, antioxidant, and hypoglycaemic properties. In Ayurvedic medicine, G. sylvestre is considered a digestive, anti-inflammatory, bitter, acrid, and liver tonic.
Traditionally, Ayurveda uses dried and powdered leaves, and less commonly roots, in formulations to balance blood sugar and promote digestive health. One unique aspect of Gymnema Sylvestre's traditional usage is its association with sweetness suppression; in Ayurvedic practices, chewing Gymnema leaves was believed to temporarily hinder the ability to taste sweetness.
Tribal and Regional Uses in India
Various parts of this plant are used by different tribes in India — including the Sahariya tribe of Madhya Pradesh, Junglee Irulas of Nilgiri hills, Kol tribe of Chhattisgarh, and the Nayaks of Karnataka — primarily to treat asthma, eye and gastric problems, parkinsonism, urinary problems, and diabetes.
Broader Traditional Uses
In Eastern and Ayurvedic medicine, G. sylvestre leaves and extracts have been used to treat eye diseases, allergies, constipation, cough, dental caries, obesity, stomach ailments, and viral infections. The plant has also been used as an antioxidant, antimicrobial, and aphrodisiac.
The leaves have also been used for stomach ailments and constipation. Distribution of the plant's use is worldwide, and it is recognized in the traditional medicine of many countries including Australia, Japan, and Vietnam. In Japan, 50 tons of G. sylvestre leaves are consumed annually for the purpose of weight loss.
Early Scientific Investigation
In the 1920s, preliminary scientific studies found some evidence that gymnema leaves could reduce blood sugar levels, but nothing much came of this for decades. Research in India picked up again in the 1980s and 1990s, leading to the publication of promising preliminary studies in people.
3. Key Constituents and Active Compounds
Primary Phytochemicals
G. sylvestre leaves contain triterpene saponins belonging to oleanane and dammarene classes. Oleanane saponins are gymnemic acids and gymnemasaponins, while dammarene saponins are gymnemasides.
Numerous active phytoconstituents, including a group of triterpene saponins known as gymnemic acids, gymnemasaponins, and the polypeptide gurmarin, have been identified in Gymnema and credited with various antioxidant, hypoglycemic, and beta cell–regenerative effects.
Gymnemic acids consist of gymnemic acids I–VII, gymnemosides A–F, gymnemasaponins, and related compounds. Gymnemic acid A is comprised of gymnemic acids A1, A2, A3, and A4, collectively called gymnemagenin. This constituent is a D-glucuronide of hexahydroxy-triterpene and esterifies with acids.
Additional Constituents
Other plant constituents include flavones, anthraquinones, hentri-acontane, pentatriacontane, α- and β-chlorophylls, phytin, resins, d-quercitol, tartaric acid, formic acid, butyric acid, lupeol, β-amyrin related glycosides, and stigmasterol. The plant extract also tests positive for alkaloids. The plant was also observed to have tannins, quinones, flavonoids, and phenols.
Trace alkaloids include gymnamine and its hydroxyl derivative, 8-hydroxy gymnamine. A 35 amino acid-long polypeptide called gurmarin has also been isolated, but its pharmacology is primarily related to sweet-taste-suppression in rodents.
Stems of Gymnema sylvestre were investigated using chromatographic techniques and were found to have several therapeutically important chemical compounds such as stigmasterol and triterpenoid saponin. From stems, seven compounds were isolated, including conduritol A, stigmasterol, lupeol, stigmasterol-3-O-β-D-glucoside, and several complex oleanane saponins.
4. Mechanisms of Action
Sweet Taste Receptor Inhibition
Gymnemic acids are considered sweetness inhibitors: after chewing the leaves, solutions sweetened with sugar taste like water. These acids suppress the sweetness of most sweeteners, including intense artificial sweeteners such as aspartame and natural sweeteners such as thaumatin.
The atomic arrangements of gymnemic acids at the taste buds are similar to sugar molecules, which fill the receptors in the taste buds, preventing activation by sugar molecules in the food. Application of gymnemic acids inhibited intracellular calcium responses to sweet compounds in HEK293 cells expressing human TAS1R2+TAS1R3 but not in those expressing the mouse sweet receptor Tas1r2+Tas1r3. This demonstrates a human-specific receptor selectivity. This temporary effect is highly selective, as the extract does not interfere with the perception of other primary tastes, such as salty, sour, or bitter.
Inhibition of Intestinal Glucose Absorption
In the intestine, gymnemic acids attach to receptors present in the external layer of the intestine, thereby preventing the absorption of sugar molecules, which leads to reduced blood glucose levels. This action is thought to be related to the inhibition of sodium-dependent glucose transporters (SGLTs) in the intestinal lining.
Stimulation of Insulin Secretion and Pancreatic Effects
The mechanisms by which G. sylvestre exerts its hypoglycemic effects include: (1) increases in insulin secretion; (2) promotion of regeneration of islet cells; (3) increases in the utilization of glucose through increased activities of enzymes responsible for glucose utilization by insulin-dependent pathways, increased phosphorylase activity, decreased gluconeogenic enzymes, and decreased sorbitol dehydrogenase; and (4) inhibition of glucose absorption from the intestine.
Several studies have attributed the hypoglycemic effects of ingested Gymnema extracts to reduced intestinal glucose uptake and increased insulin release. Gymnema sylvestre contains gymnemic acids, saponins, and flavonoids, which enhance insulin secretion, regenerate pancreatic β-cells, inhibit intestinal glucose absorption, and improve glucose uptake in peripheral tissues.
Potential Insulin Resistance Effects
One of the mechanisms responsible for adult-onset diabetes mellitus is a form of insulin resistance, attributed to the inability of insulin to enter cells via the insulin receptor. Gymnema may overcome this resistance, but further studies are required to confirm this effect.
5. Scientific Evidence by Area of Use
5.1 Blood Glucose Control and Type 2 Diabetes
Evidence Summary: This is the area with the most clinical evidence, though it remains limited by small sample sizes, short durations, lack of placebo controls in early studies, and high heterogeneity in meta-analyses.
A systematic review and meta-analysis aimed to find the effect of Gymnema sylvestre supplementation on glycemic control in type-2 diabetes mellitus (T2DM), with PubMed, Cochrane Library, Google Scholar, and Science Direct searched from inception to June 2020. The meta-analysis, consisting of 10 studies with a total of 419 participants, showed that GS supplementation significantly reduces fasting blood glucose (FBG) (SMD 1.57 mg/dl, 95% CI 2.22 to −0.93, p < .0001, I² 90%), postprandial blood glucose (PPBG) (SMD 1.04 mg/dl, 95% CI 1.53 to −0.54, p < .0001, I² 80%), and glycated haemoglobin (HbA1c) (SMD 3.91, 95% CI 7.35 to −0.16%, p < .0001, I² 99%) compared to baseline. The very high I² values for all outcomes indicate substantial heterogeneity between studies, which substantially limits the certainty of these pooled estimates.
In 1990, Baskaran et al. from India reported a study which included twenty-two patients with type 2 diabetes treated with oral anti-diabetics. The patients received the leaf extract of Gymnema sylvestre at a dose of 400 mg daily for 18–20 months. Fasting plasma glucose, glycated hemoglobin, and glycosylated plasma proteins were significantly reduced in T2DM patients after administering GS extract, and some patients were able to decrease the dosage or even discontinue the use of available hypoglycemic agents.
A clinical trial by Shanmugasundaram et al. examined a separate study in type 2 diabetes. A study conducted on 58 patients with type 2 diabetes mellitus for 90 days resulted in the reduction of fasting (p < 0.005) and postprandial blood glucose levels (p < 0.001) along with a reduction of triglycerides (p < 0.05).
A small randomized, double-blind, placebo-controlled clinical trial was also conducted. This trial was carried out in 24 patients (without pharmacological treatment), 30–60 years old, with a diagnosis of metabolic syndrome. Patients were randomly assigned to receive G. sylvestre or placebo twice daily before breakfast and dinner in 300 mg capsules for a total of 600 mg per day for 12 weeks.
Significant (p < 0.05) reduction in blood glucose level was observed in a study where 32 human subjects with type-2 diabetes were administered with Gymnema sylvestre leaf powder in hard gelatin capsules for 30 days. Reduction in triglyceride, cholesterol, and LDL level was also observed.
Clinical studies investigating antidiabetic effects have typically used 200 or 400 mg extract daily standardized to contain 25% gymnemic acids. A total daily dose of 500 to 1,000 mg/day of leaf extract given in twice daily divided doses has been administered for a duration of 2 or 3 months in clinical trials. Early, small clinical studies found decreases in mean glycosylated hemoglobin (HbA1c), fasting blood glucose, and mean daily preprandial plasma glucose for patients with type 1 and 2 diabetes receiving gymnema extracts in addition to other treatments.
Limitations of the available evidence include notable heterogeneity, low quality of studies, and lack of diversity among research participants. Outcomes suggest that GS supplementation may improve cardiovascular risk factors, but future large, high-quality RCTs with longer duration and various populations are needed to firmly establish clinical efficacy.
5.2 Type 1 Diabetes
Evidence Summary: Preliminary clinical data exists, but the body of evidence is even smaller and methodologically weaker than for type 2 diabetes.
In a study where 64 individuals with type 1 diabetes were treated with Gymnema leaf extract for 6 to 30 months, results showed reductions in plasma glucose level, reduced external insulin dose, and significant reduction in HbA1c (p < 0.001).
Shanmugasundaram and colleagues conducted a study in 27 patients with type 1 diabetes mellitus, ranging from 10 to 50 years of age, who were given 400 mg/day of Gymnema sylvestre over a period of 30 months as a complementary treatment for insulin therapy. Improvement in glycemic control after administration was associated with increased circulating insulin levels (24 ± 9 vs. 32 ± 6 U/mL, p < 0.001) and a corresponding increase in C-peptide (298 ± 42 vs. 447 ± 48 pmol/L, p < 0.05) in patients. The increase in endogenous C-peptide in type 1 patients was interpreted as indicative of β-cell regeneration, though this interpretation remains hypothesis-generating rather than conclusive.
5.3 Metabolic Syndrome and Insulin Sensitivity
Evidence Summary: Preliminary, based on small single trials.
Gymnema sylvestre is a medicinal plant whose consumption has demonstrated benefits on lipid and glucose levels, blood pressure, and body weight. Endogenous insulin appears to be improved by GS therapy, possibly through β-cell regeneration. In T2DM patients, oral administration of GS extract revealed an insulinotropic effect, as well as significant improvement in glycemic control.
5.4 Lipid Profile (Dyslipidemia)
Evidence Summary: Mostly preclinical (animal); limited and mixed human data. Human data often confounded by concurrent antidiabetic medication or combination-product formulations.
Reductions in levels of serum triglycerides, total cholesterol, very low-density lipoprotein (VLDL), and LDL cholesterol-lowering effects have been observed in animals following administration of gymnema. The mechanism of this effect may be via decreased cholesterol synthesis, increased cholesterol metabolism, or decreased intestinal fat absorption.
In an animal study, the group administered with hydroalcoholic extract of Gymnema leaves at a dose of 200 mg/kg showed significant reduction in the levels of all lipids with an increase in HDL-C as compared to high cholesterol diet control.
Human data is more limited. In a study of 32 human subjects with type-2 diabetes administered with Gymnema sylvestre leaf powder for 30 days, reduction in triglyceride, cholesterol, and LDL level was observed. Use as a lipid-lowering agent has been investigated primarily in rodent studies.
5.5 Body Weight and Obesity
Evidence Summary: Very limited human data; results in combination-product studies cannot be attributed to gymnema alone.
Gymnemic acids curb the binding of carbohydrates to the receptors in the intestine, and hence the "empty calories" are theoretically managed so that the body does not progress to an obese state.
Decreased body weight has been demonstrated in studies using combinations of various dietary supplements, including G. sylvestre with chitosan, fenugreek, and vitamin C, and gymnema with niacin-chromium complex. The resultant weight loss cannot be attributed to a single ingredient. In contrast to weight gain experienced by the control group, suppression of weight gain was observed in a quasi-experimental study in type 2 diabetics who received adjunctive use of G. sylvestre extract.
In Japan, 50 tons of G. sylvestre leaves are consumed annually for the purpose of weight loss. Early research suggests that taking a specific combination of Gymnema sylvestre extract, hydroxycitric acid, and niacin-bound chromium by mouth for 8 weeks might reduce body weight in people who are overweight or obese. Again, attribution to gymnema specifically in combination studies cannot be made.
5.6 Anti-inflammatory and Antioxidant Activity
Evidence Summary: Primarily in vitro and animal data; no controlled human trials identified for these endpoints specifically.
In vitro and in vivo investigations of the therapeutic importance of Gymnema sylvestre revealed multifarious pharmacological potentials including anti-cancer, immunosuppressive, gastro-protective, hypoglycemic, anti-inflammatory, anti-infectious, and most importantly anti-diabetic activities. Gymnema sylvestre is also known to have anti-oxidant, antibiotic, anti-inflammatory, antiviral, gastro- and hepatoprotective, anticancer, and lipid-lowering activities. These findings are predominantly from laboratory and animal studies.
5.7 Dental Caries
Evidence Summary: Theoretical, based on the sweet-suppression mechanism; no controlled human trials identified.
Use for the inhibition of caries has been investigated, primarily in rodent studies, but limited clinical information is available to support its use for this indication.
6. Body Systems and Health Areas of Association
- Endocrine / Metabolic System: Regulation of blood glucose, insulin secretion, and pancreatic β-cell function are the primary documented associations. G. sylvestre has good prospects in the treatment of diabetes as it shows positive effects on blood sugar homeostasis, controls sugar cravings, and promotes regeneration of the pancreas.
- Cardiovascular System: There is growing interest in the potential health benefits of Gymnema Sylvestre supplementation, as some studies have reported that it may improve cardiometabolic risk factors. This includes preliminary data on lipid profiles.
- Gustatory (Taste) System: The Indian herb Gymnema sylvestre reversibly inhibits the sensation of sweet, presumably by blocking sucrose receptors. The herb has dual mechanisms of action, evidenced by the fact that it has been used for centuries in Ayurvedic medicine for the treatment of diabetes.
- Gastrointestinal System: Gymnema sylvestre has historically been used in Ayurveda to promote healthy digestion alongside its blood sugar benefits.
- Hepatic System: In an in vitro investigation, a hydro-alcoholic extract of Gymnema sylvestre was observed to render anti-hepatotoxic function in a dose-dependent manner in isolated rat hepatocytes where hepatotoxicity was induced using D-galactosamine. However, human data are very limited and a small number of case reports raise concerns (see Safety section).
7. Dosage Forms and Reported Dosages
Dietary supplements and teas that contain gymnema are usually made from the leaves that grow on the vine. Commercial presentations include standardized leaf extracts in capsule or tablet form, loose dried leaf powder, and leaf teas.
The following dosages are reported from clinical and research sources only:
- Clinical studies investigating antidiabetic effects have typically used 200 or 400 mg extract daily standardized to contain 25% gymnemic acids.
- A total daily dose of 500 to 1,000 mg/day of leaf extract given in twice-daily divided doses has been administered for a duration of 2 or 3 months in clinical trials.
- One randomized, double-blind, placebo-controlled clinical trial used 300 mg capsules twice daily (600 mg/day total) for 12 weeks in patients with metabolic syndrome.
- A complementary-therapy study in type 1 diabetes used 400 mg/day over a period of 30 months alongside insulin therapy.
- One study evaluated control of type 2 diabetes with Gymnema sylvestre at a dose of 1 g/day divided into two doses for 30 days.
- Mild side effects, such as diarrhea, stomach cramps, and headache, were reported in one study that used a dosage of 600 mg daily.
- Gymnema is also noted in reference sources as being taken at a dosage of 400 to 600 milligrams daily of an extract standardized to contain 24 percent gymnemic acid.
There is no officially established safe dose for gymnema, partly because supplements vary widely in how they are prepared and how concentrated their active compounds are. The doses that have been studied in humans range considerably.
8. Safety Considerations and Drug Interactions
General Tolerability
Limited evidence from toxicological in vivo studies and human clinical studies suggests a lack of relevant adverse effects of this botanical. The main drawbacks of Gymnema sylvestre include mild side effects (such as diarrhea and headaches), potential hypoglycemia, and limited safety data, particularly in humans. GS is considered safe at doses of up to 10 grams per day; the recommended daily dose of 400 mg is unlikely to produce any toxic effects.
Hypoglycemia Risk
Human studies provided some indications that certain Gymnema extracts may enhance the glucose-lowering effects of certain antidiabetic drugs. Considering the uncertainties for the composition of different Gymnema preparations, potential herb–drug interactions, and the indications of glucose-lowering or hypoglycaemic effects, the use of Gymnema-based food supplements in combination with authorised antidiabetic drugs may be associated with risks.
Considering the uncertainties for the composition of different Gymnema preparations, potential herb–drug interactions, and the concerns about glucose-lowering or hypoglycaemic effects, the use of Gymnema-based food supplements in combination with (or as a substitute for) authorised antidiabetic drugs may be associated with risks when used without medical supervision.
Hepatotoxicity
There have been isolated rare reports of liver injury from herbal products containing Gymnema sylvestre, but attribution to the herb was usually weak. Authors of a published case report noted that they were unable to find previous reports associating G. sylvestre with liver injury; they reported a case of drug-induced liver injury (DILI) in a patient treated with G. sylvestre for diabetes mellitus and reviewed the literature to suggest possible mechanisms.
A published case report of liver toxicity related to the consumption of a Gymnema tea could point to potential adulteration or contamination of the tea with hepatotoxic substances or to a hepatotoxic potential of certain G. sylvestre constituents. However, in the light of preliminary evidence from animal studies, rather potential hepatoprotective effects of Gymnema preparations were observed.
Among 839 cases of liver injury from drugs collected in the US between 2004 and 2013 (US Drug-Induced Liver Injury Network), 130 were due to herbal and dietary supplement products, but no case was attributed specifically to Gymnema sylvestre.
Cytochrome P450 Interactions
Phytoconstituents contained in GS, particularly in ethyl acetate and chloroform extracts, were able to inhibit CYP1A2, CYP3A4, and CYP2C9. The presence of relatively small, lipophilic yet slightly polar compounds within the GS extracts may be responsible for these inhibition activities. These suggest that the herb or its extracts should be examined for potential pharmacokinetic drug interactions in vivo. These findings are from in vitro (human liver microsome) experiments; their clinical significance at standard supplement doses has not been established in human pharmacokinetic trials.
Evidentiary Gaps for Risk Assessment
Presently, there are considerable knowledge gaps for the risk assessment of G. sylvestre preparations, and open questions remain as to whether results obtained with one preparation can be extrapolated to another Gymnema preparation. Based on the lack of systematic data on dose and effect relationships, the available information was regarded as not being sufficient for the derivation of health-based guidance values for Gymnema or Gymnema preparations.
Variations in plant preparations and possible interactions with medications, especially those for diabetes, complicate the safety evaluation of this botanical.
References
- Gymnema sylvestre: A Memoir — PMC (PubMed Central)
- Comprehensive Review on Phytochemicals, Pharmacological and Clinical Potentials of Gymnema sylvestre — Frontiers in Pharmacology / PMC
- Phytochemical and Pharmacological Properties of Gymnema sylvestre: An Important Medicinal Plant — PMC
- The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis — Phytotherapy Research (Wiley)
- The effects of Gymnema Sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: A systematic review and meta-analysis — PubMed
- Effect of Gymnema sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion — PubMed
- Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre — PMC (EFSA Journal)
- Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre — EFSA Journal (Wiley)
- Human Cytochrome P450 Enzyme Modulation by Gymnema sylvestre: A Predictive Safety Evaluation by LC-MS/MS — PMC
- Gymnema — LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury, NCBI Bookshelf (NIDDK)
- Toxic hepatitis induced by Gymnema sylvestre, a natural remedy for type 2 diabetes mellitus — PubMed (American Journal of the Medical Sciences)
- Gymnema Sylvestre Supplementation Restores Normoglycemia, Corrects Dyslipidemia, and Transcriptionally Modulates Pancreatic and Hepatic Gene Expression in Alloxan-Induced Hyperglycemic Rats — PMC
- Use of the Herb Gymnema sylvestre to Illustrate the Principles of Gustatory Sensation: An Undergraduate Neuroscience Laboratory Exercise — PMC
- Evaluation of antiobesity and cardioprotective effect of Gymnema sylvestre extract in murine model — PMC
- Hypolipidaemic Effects of Gymnema sylvestre on High Fat Diet Induced Dyslipidaemia in Wistar Rats — PMC
- Gymnema sylvestre for Diabetes: From Traditional Herb to Future's Therapeutic — PubMed
- Gymnema Uses, Benefits & Dosage — Drugs.com (Natural Product Database, medically reviewed)
- Gymnema (Gymnema sylvestre) monograph — Restorative Medicine
- Gymnemic Acid — ScienceDirect Topics overview
- Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance — ClinicalTrials.gov Protocol Document (NCT02708966)
- Unlocking the anti-diabetic potential of Gymnema sylvestre, Trigonella foenum-graecum, and their combination: An in-vivo evaluation — PMC
- Combined Inositols, α-Lactalbumin, Gymnema Sylvestre and Zinc Improve the Lipid Metabolic Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial — PMC
- What are Gymnema sylvestre's main drawbacks? — Examine.com
Volver